Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Note: The archived version of this monograph has been temporarily removed. For an electronic copy of this archived version, please contact the Natural Health Products Directorate (NHPD) at NHPD_DPSN@hc-sc.gc.ca.
Archived Monograph - August 2008
This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard.
Note: Text in parentheses is additional optional information which can be included on the Product Licence Application and product labels at the applicants' discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.
Date: June 23, 2009
Proper name(s): Iron (Sweetman 2007; O'Neil et al. 2006)
Common name(s): Iron (Sweetman 2007; O'Neil et al. 2006)
Source material(s):
Note:When iron HAP or HVP chelate is used as a source material, the products should be indicated for an adult subpopulation only.
Route(s) of administration: Oral
Dosage form(s): Those pharmaceutical dosage forms suited to oral administration, including but not limited to chewables (eg. gummies, tablets), caplets, capsules, strips, lozenges, powders or liquids where the dose is measured in drops, teaspoons, or tablespoons are acceptable. This monograph is not intended to include foods or food-like dosage forms such as beverages, bars or chewing gums.
Use(s) or Purpose(s): Statement(s) to the effect of:
General: A factor in the maintenance of good health (IOM 2006; IOM 2001)..
Specific: Helps to form red blood cells and helps in their proper function (IOM 2006; Shils et al. 2006; IOM 2001; Groff and Gropper 2000).
Dose-specific: For products providing daily doses of iron at or above the Recommended Dietary Allowance (RDA) or Adequate Intake (AI) (adjusted for the life stage groups), either of the following use or purpose statements are acceptable provided that they are used verbatim:
For products providing daily doses of iron between 16-20 mg:
Notes:
Dose(s):
Table 1: Dose information for iron presented as dose per day
| Life stage group | Iron (mg/day) | ||
|---|---|---|---|
| Minimum1 | Maximum2 | ||
| Infants | 0-12 mo | 0.6 | 40 |
| Children | 1-3 y | 0.6 | 40 |
| 4-8 y | 0.6 | 40 | |
| Adolescents | 9-13 y | 0.6 | 40 |
| 14-18 y | 1.4 | 45 | |
| Adults3 | ≥ 19 y | 1.4 | 45 |
Directions for use: Statement(s) to the effect of:
Duration of use: No statement required.
Risk information: Statement(s) to the effect of:
Caution(s) and warning(s):
If the package contains more than the equivalent of 250 mg of elemental iron:
Keep out of reach of children. There is enough drug in this package to seriously harm a child. (Note: This must be preceded by a prominently displayed symbol that is octagonal in shape, conspicuous in colour and on a background of a contrasting colour) (As per Section 97 of the Natural Health Product Regulations, citing Sections C.01.029 and C.01.031 of the Food and Drug Regulations (JC 2009a,b)).
Contraindication(s): No statement required.
Known adverse reaction(s):
For products targeted to pregnant women, providing iron at doses 16-35 mg per day, the following statement is required:
Taking a daily prenatal multi-vitamin mineral supplement along with this product may result in constipation, diarrhoea, and/or vomiting due to the high intake of iron (IOM 2006; IOM 2001).
For all products providing iron at doses greater than 35 mg, per day, the following statement is required:
Some people may experience constipation, diarrhoea, and/or vomiting (IOM 2006; IOM 2001).
Non-medicinal ingredients:
Must be chosen from the current NHPD Natural Health Products Ingredients Database and must meet the limitations outlined in the database.
Specifications:
References cited:
Albion 2003: Albion Advanced Nutrition. The Iron Conundrum. Albion Research Notes 12(1) [online]. Clearfield (UT): Albion Advanced Nutrition, Inc. [Accessed 2009 April 17]. Available from: http://www.news.albionminerals.com/human-nutrition/research-notes-pdf/doc_details/321-the-iron-conundrum
Albion 2000: Albion Laboratories. Implications of the "Other Half" of a Mineral Compound. Albion Research Notes 9(3) [online]. Clearfield (UT): Albion Laboratories, Inc. [Accessed 2009 April 17]. Available from: http://www.news.albionminerals.com/human-nutrition/research-notes-pdf/doc_details/738-implications-of-the-qother-halfq-of-a-mineral-compound
Albion 1997: Albion Laboratories. Is Iron Getting a Bad Rap? Albion Research Notes 6(4) [online]. Clearfield (UT): Albion Laboratories, Inc. [Accessed 2009 April 17]. Available from: http://www.news.albionminerals.com/human-nutrition/research-notes-pdf/doc_details/727-is-iron-getting-a-bad-rap
Albion 1996: Albion Laboratories. Iron Product Safety Issue / A Non-issue for Albion's Ferrochel! Albion Research Notes 5(1) [online]. Clearfield (UT): Albion Laboratories, Inc. [Accessed 2009 April 17]. Available from: http://www.news.albionminerals.com/human-nutrition/research-notes-pdf/doc_details/723-iron-products-safety-issue-a-non-issue-for-albions-ferrochel
Albion 1993: Albion Laboratories. Iron Treatment Failure. Albion Research Notes 2(6) [online]. Clearfield (UT): Albion Laboratories, Inc. [Accessed 2009 April 17].
Available from: http://www.news.albionminerals.com/human-nutrition/research-notes-pdf/doc_details/712-iron-treatment-failure
Allen LH. 2002. Advantages and limitations of iron amino acid chelates as iron fortificants. Nutrition Reviews 60(7):S18-S21.
ASHP 2005: American Society of Health-System Pharmacists. American Hospital Formulary Service (AHFS) Drug Information. Philadelphia (PA): Lippincott Williams and Wilkins.
Groff J, Gropper S. 2000. Advanced Nutrition and Human Metabolism, 3rd edition. Belmont (CA): Wadsworth/Thomson Learning.
HC 2008: Health Canada. 2008. Drug Product Database [online]. Ottawa (ON): Health Canada. [Accessed 2009 April 17]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php
IOM 2006: Institute of Medicine. Otten JJ, Pitzi Hellwig J, Meyers LD, editors. 2006. Institute of Medicine Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington (DC): National Academies Press.
IOM 2003: Institute of Medicine. Committee on Food Chemicals Codex, Food and Nutrition Board. 2003. Food Chemicals Codex, 5th edition. Washington (DC): National Academies Press.
IOM 2001: Institute of Medicine. Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. 2001 Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington (DC): National Academy Press.
IPCS 1998. International Program on Chemical Safety. International Agency for Research on Cancer (IARC) - Summaries & Evaluations: Iron-carbohydrate Complexes. Volume 2 (1973) p. 161. [online]. Geneva (CHE): World Health Organization on behalf of the IPCS (World Health Organization, United Nations Environment Programme, International Labour Organisation). [Accessed 2009 April 17]. Available from: http://www.inchem.org/documents/iarc/vol02/iron.html
JC 2009a: Department of Justice Canada. Natural Health Products Regulations. Section 97, Cautionary Statements and Child Resistant Packages. [online]. Ottawa (ON): Department of Justice Canada. [Accessed 2009 May 22]. Available from: http://laws.justice.gc.ca/en/showtdm/cr/SOR-2003-196//?showtoc=&instrumentnumber=SOR-2003-196.
JC 2009b: Department of Justice Canada. Food and Drug Regulations. C.01.029 and C.01.031, Cautionary Statements and Child Resistant Packages. [online]. Ottawa (ON): Department of Justice Canada. [Accessed 2009 May 22]. Available from: http://laws.justice.gc.ca/en/F-27/C.R.C.-c.870/text.html.
O'Neil MJ, Smith A, Heckelman PE, Budavari S, editors. 2006. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th edition. Whitehouse Station (NJ): Merck & Co., Inc.
O'Neil MJ, Smith A, Heckelman PE, Budavari S, editors. 2001. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th edition. Whitehouse Station (NJ): Merck & Co., Inc.
Shils ME, Olson JA, Shike M, Ross AC, Caballero B, Cousins RJ, editors. 2006. Modern Nutrition in Health and Disease, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins.
Sweetman SC, editor. 2007. Martindale: The Complete Drug Reference, 35th edition. London (UK): Pharmaceutical Press.
Adequate Intake (AI): The recommended average daily intake level based on observed or experimentally determined approximations or estimates of nutrient intake by a group (or groups) of apparently healthy people that are assumed to be adequate; used when an RDA cannot be determined.
Recommended Dietary Allowances (RDA): The average daily dietary nutrient intake level sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals in a particular life stage and gender group (IOM 2006).
Tolerable Upper Intake Level (UL): The highest average daily nutrient intake level that is likely to pose no risk of adverse health effects to almost all individuals in the general population. As intake increases above the UL, the potential risk of adverse effects may increase (IOM 2006).
Appendix 2: RDA and AI Values
The AI (as indicated by an asterisk) and RDA values for iron are provided below. For the purpose of this monograph, these values are intended to:
Table 2: Recommended Dietary Allowance and Adequate Intake* values for iron based on life stage group (IOM 2006)
| Life stage group | Iron (mg/day) | |
|---|---|---|
| Infants | 0-6 mo | 0.27* |
| 7-12 mo | 11 | |
| Children | 1-3 y | 7 |
| 4-8 y | 10 | |
| Adolescent males | 9-13 y | 8 |
| 14-18 y | 11 | |
| Adult males | ≥ 19 y | 8 |
| Adolescent females | 9-13 y | 8 |
| 14-18 y | 15 | |
| Adult females | 19-50 y | 18 |
| ≥ 51 y | 8 | |
| Pregnancy | 14-50 y | 27 |
| Breastfeeding | 14-18 y | 10 |
| 19-50 y | 9 | |